197 related articles for article (PubMed ID: 20171385)
1. Chemo-immunotherapy in RCC: the end of a story.
Escudier B
Lancet; 2010 Feb; 375(9715):613-4. PubMed ID: 20171385
[No Abstract] [Full Text] [Related]
2. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
3. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
4. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
5. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
6. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
7. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
8. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
Amato R
Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
[No Abstract] [Full Text] [Related]
9. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
10. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
11. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
Huland E; Heinzer H
Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
[No Abstract] [Full Text] [Related]
12. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
[TBL] [Abstract][Full Text] [Related]
13. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in metastatic renal cell carcinoma.
Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
[TBL] [Abstract][Full Text] [Related]
15. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
[TBL] [Abstract][Full Text] [Related]
16. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
Kirkali Z
Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
[No Abstract] [Full Text] [Related]
17. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
18. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
Vieweg J
Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
[No Abstract] [Full Text] [Related]
19. Immunotherapy for renal cell carcinoma.
Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
[TBL] [Abstract][Full Text] [Related]
20. Of snails and holy grails..
Yang JC
Cancer J Sci Am; 1997; 3(3):142-3. PubMed ID: 9161778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
